January 26, 2021
MarketScreener
Genmab Announces 2020 Net Sales of DARZALEX (daratumumab)
(marketscreener.com) Company Announcement Net sales of DARZALEX® in 2020 totaled USD 4,190 millionGen... See more »
Press Release: Oxford BioTherapeutics : Oncology Research: New Opportunities for Menarini and OBT
POMEZIA, Italy and OXFORD, England, September 12, 2017 /PRNewswire/ -- Oncology Alliance between Menarini & Oxford BioTherapeutics Progresses Second Candidate MEN1309 into the Clinic, an Antibody Drug Conjugate for the treatment of solid tumors and&nbs...
Read full article »Today 11:08 AM
Pharmabiz
Merck, Pfizer's Bavencio gets EC approval to treat locally advanced or metastatic urothelial carcinoma
Merck and Pfizer Inc announced that the European Commission (EC) has approved Bavencio (avelumab) as ... See more »
January 26, 2021
MarketScreener
Genmab Announces 2020 Net Sales of DARZALEX (daratumumab)
(marketscreener.com) Company Announcement Net sales of DARZALEX® in 2020 totaled USD 4,190 millionGen... See more »
Today 11:08 AM
Pharmabiz
Merck, Pfizer's Bavencio gets EC approval to treat locally advanced or metastatic urothelial carcinoma
Merck and Pfizer Inc announced that the European Commission (EC) has approved Bavencio (avelumab) as ... See more »
Est. Annual Revenue
Est. Employees
Founder & CEO
Christian Rohlff
OBT is a biotechnology company that focuses on the discovery and development of therapeutics for the treatment of cancer. Read more
